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Objectives: To assess the performance indicators of visual inspection with acetic acid (VIA) and visual
inspection with Lugol’s iodine (VILI) in four Latin American centres participating in the ongoing Latin
AMerican Screening (LAMS) study, in settings with moderate incidence of cervical disease and with
poorly to moderately well-organized cervical cancer screening.
Setting: Three Brazilian centres (Sa˜o Paulo, Campinas and Porto Alegre) and one Argentine centre
(Buenos Aires) recruited a total of 11,834 healthy women to undergo VIA, VILI, conventional Pap
smear and Hybrid Capture II (HCII).
Methods: Women who had a positive result from any of these tests were subjected to colposcopy and
biopsies (if necessary), and women with high-grade cervical intraepithelial neoplasia (CIN) were
properly treated. To control for verification bias, 5% of women with normal tests were referred for
colposcopy, as were 20% of HCII-negative women.
Results: Data on VIA (n¼11,834), VILI (n¼2994), conventional Pap smear (n¼10,138) and HCII
(n¼4195) were available for test comparisons, calculating sensitivity, specificity, and positive and
negative predictive values. Overall test positivity was 11.6% for VIA, 23.0% for VILI, 2.2% for Pap
smear (LSIL threshold), 1.1% for Pap smear (HSIL threshold) and 17.1% for HCII. VIA was positive in
61.8% of the women with CIN 1, 57.0% of those with CIN 2, 35.0% of women with CIN 3 and in 21
of 28 (75%) of women with cancer. Approximately 10% of women with no detectable disease had an
abnormal VIA. Regarding VILI, 83.3% of women diagnosed with CIN 1 and 62.5% of those with CIN
3 had an abnormal test. VILI failed to detect one of three cases of cancer. Both the sensitivity, specificity
and positive predictive value of VIA and VILI in detecting CIN 2 or CIN 3 could be significantly
improved depending on the combination with Pap smear or HCII (sensitivity up to 100.0% and
specificity up to 99.8%).
Conclusions: The LAMS study failed to reproduce the performance figures obtained with VIA and VILI
(as stand-alone tests) in some other settings, where the prevalence of cervical disease was higher.
However, a combined use of VIA or VILI with the Pap test or HCII allowed specific detection of cervical
abnormalities.
INTRODUCTION
Severely affected by the lack of human and material
resources, many economically underprivileged geographic
regions fail to provide efficient screening for cervical
cancer.1,2 The current mainstay of cervical cancer screening,
cervical cytology (Pap smear), necessitates a well-organized
infrastructure to achieve optimal results: health units to
collect cervical material, laboratories to prepare the slides for
reading, specialized personnel apt to render a diagnosis and,
ultimately, physicians trained to deal with the abnormalities
eventually detected.3 This structure is not readily available,
and only a few countries have managed to consistently
reduce their cervical cancer incidence and prevalence rates
by widespread use of Pap smear screening, most notably the
Nordic Countries.4–6
Prompted by the need for optimal strategies for cervical
cancer screening, and based upon the concepts that the
majority of pre-invasive and invasive cervical lesions are
visible by ‘naked-eye’ observation, investigators have
developed novel affordable diagnostic tools suitable for
large-scale screening of cervical abnormalities.7 Visual
Inspection with Acetic Acid (VIA) and Visual Inspection
with Lugol’s Iodine (VILI) are two modifications of a direct
visual assessment of the cervix, different only in regard to
the solutions applied to enhance the cervical lesions.
Several recent studies testing VIA suggest that it closely
matches the Pap smear in its performance in detecting
cervical cancer precursors.7,8 In a recent report on 4444
women, VILI was also shown to perform adequately,9 being
comparable to both VIA and the Pap smear.10,11 However,
several weaknesses of VIA and VILI have been revealed,
particularly the high rate of false-positive findings, which
may lead to substantial number of colposcopies.11–13
Importantly, more work is needed to evaluate the perfor-
mance of these new tools under field conditions, and on
implementing VIA and VILI in countries with different
cancer incidence and in different screening settings.
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The authors recently designed a multi-centre study testing
eight different screening tools in a cohort of over 12,000
women enrolled by four clinics in regions of Brazil and
Argentina with different incidence of cervical cancer,
known as the Latin AMerican Screening (LAMS) study.14
One of the two major aims of this study is to evaluate the
feasibility of eight different diagnostic tests, to find out the
cost-effective tools for cervical cancer screening in these
low-resource settings. VIA and VILI are included in the
repertoire of these eight diagnostic tests to be compared in
the LAMS study. The present communication reports the
performance of VIA and VILI, used as a stand-alone test and
combined with other tests in detecting significant cervical
pathology in our setting.
MATERIALS ANDMETHODS
Study design
LAMS is an ongoing, cross-sectional, multi-centre study
sponsored by the European Commission through its
INCO–DEV partnership (ICA4-CT2001-10013). In this study,
consecutive women from the cities of Campinas (Brazil),
Sa˜o Paulo (Brazil), Porto Alegre (Brazil) and Buenos Aires
(Argentina) were recruited to undergo gynaecological
consultations and examination with conventional Pap
smear, VIA and VILI, cervicography and screening colpo-
scopy. Women were sampled for human papilloma virus
(HPV) by Hybrid Capture II (HCII). All centres performed
conventional Pap smear, HCII and VIA, but only Porto
Alegre was assigned to perform VILI (Figure 1). In order to
ensure homogeneous exams quality, all centres provided
specialists in gynaecology and well-trained nurses to carry
out the specimen collection for HCII and Pap, as well as to
perform VIA and VILI. No exact numbers are available
on how many exams have been collected/performed by
each of these professionals. Altogether, 11,834 women were
examined with VIA, 2994 with VILI, 10,138 had conven-
tional Pap test, and 4195 with HCII at the first clinical visit.
Figure 1 depicts the number of women enrolled by each
centre. The study protocol has been approved by the
local Ethics Committees of all participating clinics. All
enrolled women gave their agreement to participate by
signing the Informed Consent Forms written in their native
language.
Study centres and demographics
Campinas is a city of one million inhabitants, situated in the
southeast region of Brazil approximately 100 km from Sa˜o
Paulo city. The city is a dynamic commercial and industrial
centre, with a relatively well-structured health system and
some high-standard hospitals. However, a substantial
proportion of the population (almost 20%) living on the
outskirts of the city is composed of people who migrated
from the north and northeast (the poorest) regions of the
country, searching for jobs. In Sa˜o Paulo state, encompass-
ing the cities of Campinas and Sa˜o Paulo, cervical cancer is
the fourth major cause of cancer death among women,
accounting for 3.3% of all female deaths due to cancer.
In this region, breast cancer accounted for 13.3% of
cancer deaths among women between 1995 and 1999.15
Women have been enrolled in the Centro de Atenc- a˜o
Integral a` Sau´de da Mulher (CAISM), a State University of
Campinas’ (UNICAMP) teaching hospital, dedicated to the
care of women, and in a basic health unit in the outskirts
of the city.
Sa˜o Paulo city is the economic powerhouse of Brazil, with
11 million inhabitants. Its population is composed of a
multiple ethnic groups (European whites, Asians and
African–Americans). Health care is heterogeneous, ranging
from overcrowded public basic health units and hospitals to
a high-quality private sector. In this city, women have been
enrolled by the Hospital Leonor Mendes de Barros, a public
institution which performs over 50,000 gynaecological and
obstetric consultations every year.
Porto Alegre is the capital of Rio Grande do Sul state, in
the south of Brazil. The state’s population enjoys the best
C O L P O S C O P Y
All normal (n=2078)
Campinas
n=2472
Abnormal (%) / Normal (%)
VIA 168 (6.8) / 2299 (93.2)
Pap 39 (1.6) / 2388 (98.4)
HCII 260 (18.8) / 1121 (81.2)
Campinas
Significant lesion = 29
CIN 2 = 21
CIN 3 = 6
Cancer = 2
All normal (n=2473)
São Paulo
n=2994
Abnormal (%) / Normal (%)
VIA 387 (12.9) / 1606 (87.1)
Pap 30 (2.2) / 1342 (97.8)
HCII 132 (16.4) / 371 (83.6)
São Paulo
Significant lesion = 20
CIN 2 = 8
CIN 3 = 9
Cancer = 3
All normal (n=2135)
Porto Alegre
n=2974
Abnormal (%) / Normal (%)
VIA 489 (16.4) / 2483 (83.6)
Pap 68 (2.3) / 2872 (97.7)
HCII 167 (15.5) / 912 (84.5)
VILI 688 (23.0) / 2306 (77.0)
Porto Alegre
Significant lesion = 39
CIN 2 = 12
CIN 3 = 24
Cancer = 3
All normal (n=2881)
Buenos Aires
n=3402
Abnormal (%) / Normal (%)
VIA 333 (9.8) / 3069 (90.2)
Pap 88 (2.6) / 3311 (97.4)
HCII 158 (16.9) / 774 (83.1)
Buenos Aires
Significant lesion = 74
CIN 2 = 13
CIN 3 = 41
Cancer = 20
Screening colposcopy
(n=872) + 5% random ~5% colposcopy (random) Screening colposcopy (all)~5% colposcopy (random)
Figure 1 Screening test results for each study centre and final disease status. Significant lesion¼CIN 2 or worse.
VIA and VILI as optional screening tools in Latin America 143
www.jmedscreen.com Journal of Medical Screening 2005 Volume 12 Number 3
levels of quality of life in the country, although cervical
cancer is the sixth major cause of cancer death among
women, accounting for 6.10% of all female deaths due to
cancer. In this region, breast cancer accounted for 15.1% of
cancer deaths among women from 1995 to 1999.15. The
participant centre was Hospital de Clı´nicas de Porto Alegre, a
general hospital affiliated to Federal University of Rio
Grande do Sul. The department of Obstetrics and Gynaecol-
ogy of this centre is responsible for roughly 30,000
gynaecological and obstetrical consultations per year.
Buenos Aires is the capital of Argentina, and the
participating centre in this country was Hospital de Clı´nicas
Jose´ de San Martin, a general teaching hospital with large
experience with gynaecology and obstetrics, and being a
reference centre for colposcopy for the entire country. The
country has an overall cervical cancer mortality rate of 7.6
per 100,000 women.16
Enrolment and eligibility
Slightly different protocols were used to recruit the women
in different clinics. In Sa˜o Paulo, Porto Alegre and Buenos
Aires, eligible women (see below for criteria) were informed
of the study protocol by their local health units, inviting
them to participate. In Campinas, in addition to this
approach, students and employees of the University Hospital
were also informed and invited through an open advertise-
ment, widely distributed in the university facilities.
Women were considered eligible if they met all of the
following requirements:
 were aged 18–60 years;
 had an intact uterus (i.e. no previous surgical procedure
of the cervix or corpus);
 had no history of abnormal Pap test in the past year;
 were not under treatment for genital condyloma
(external or in the cervix);
 had no sexual intercourse during the three days prior to
the consultation;
 did not have any confirmed or clinically suspected
immunosuppression (HIV, corticosteroids, chemother-
apy, other chronic diseases that might compromise the
immune system).
Diagnostic setting
After signing the Informed Consent Form, women were
subjected to a questionnaire addressing clinical and epide-
miological risk factors of cervical disease (e.g. HPV). All
women were subjected to a thorough pelvic examination, in
this sequence comprising collection of the Pap smear,
collection of the HCII sample and VIA. In Porto Alegre,
most women were subjected to VILI shortly after they had
been examined using VIA. Women who had one or more
abnormal result were referred for colposcopic examination.
In Argentina and Campinas (CAISM), women were sub-
jected to screening colposcopy even when their exams were
negative. The decision to take a histological specimen was
based upon the Pap smear result and colposcopy. Abnormal
colposcopy prompted punch biopsies of the cervix and
women with high-grade cytological abnormalities were
referred for conization. Women had their second visit
scheduled after 45 days, to be informed about their exam/
biopsy results and to be allotted to either the treatment or
the follow-up group. Treatment was offered to all women
who had high-grade lesion confirmed in the cervical biopsy.
In all, 28 cases of cancer were diagnosed during the course
of the recruitment phase and were treated according to each
institution’s protocols.
Visual inspectionwith acetic acid (VIA)
After collection of the samples for the Pap test and HCII, 5%
acetic acid was applied to the cervix through embedded
cotton at the edge of a Cherron. After 1min, the cervix was
illuminated with a 100W bright lamp and visually exam-
ined (‘naked eye’ examination). Examiners have been
trained to classify their visual impression according to the
Atlas of Visual Inspection,8 which has many diagnostic
possibilities. For statistical purposes, these diagnosis were
grouped as negative or positive, as follows:
 negative – nulliparous, multiparous, presence of cervical
mucous, squamous metaplasia, ectropium, cervicitis,
Naboth cysts; polyps, vaginal discharge.
 positive – suggestive of condyloma, cervical intraepithe-
lial neoplasia (CIN) 1, CIN 2, CIN 3 or cancer.
Visual inspectionwith Lugol’s iodine (VILI)
Following the completion of VIA, the cervix was stained
with Lugol’s iodine and the visual impressions were
classified into three categories: normal cervix, abnormal
cervix, and cervix with suspected cancer.9.Lugol’s iodine
stains glycogen-rich vaginal epithelium cells. Proliferative
lesions, like CIN or cancer, are composed of cells that
contain less glycogen than does the surrounding epithelium.
These lesions appear as non-staining areas when Lugol is
applied to the cervix, and VILI is therefore classified as
‘abnormal cervix’. If ulcerated, friable lesions are found,
VILI has been classified as ‘suggestive of cancer’. VILI was
always performed after VIA, because Lugol’s iodine usually
stains the cervix for 30–60min, sometimes for many hours.
As with VIA, the main purpose of VILI was not to ascertain
the diagnosis, but to distinguish between a normal and an
abnormal cervix.
 negative – homogeneous staining of the cervix was
obtained after application of Lugol’s iodine.
 positive – a well-delimited non-staining area was
present.
Cervical cytology (Pap smear)
Conventional Pap smears were taken using the Ayre spatula
and endocervical brush, fixed in 95% ethanol and stained
by the modified Papanicolaou method. Final cytological
diagnoses were issued using the Bethesda System (2002)18
and were classified as normal/inflammatory, atypical squa-
mous cells (ASC), atypical glandular cells (AGC), low-grade
squamous intraepithelial lesion (LSIL) or high-grade squa-
mous intraepithelial cells (HSIL).
 negative – normal/inflammatory and ASC results.
 positive – LSIL, HSIL, and ‘suggestive of invasive
carcinoma’ (two thresholds were used for positivity:
LSIL or higher and HSIL or higher).
Hybrid capture II (HCII)
The specimens for HCII were tested with probe B (high-risk
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68)19 and the tests were classified positive at the relative
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light unit/positive control (RLU/CO) ratio of 1 pg/mL or
greater. These RLU/CO ratios provide a semi-quantitative
estimate of the amount of HPV DNA in the specimens (i.e.
the viral load in the sample). Storage of specimens and
reagents, as well as exams processing, were carried out in
manufacturer-certified laboratories, under the responsibility
of the investigators, following the manufacturer’s instruc-
tions (Digene Diagnostics Inc., USA). Sa˜o Paulo and Buenos
Aires processed their own HCII samples in-house. Campinas
and Porto Alegre had their HCII specimens processed at a
Campinas University hospital laboratory.
Colposcopy
Colposcopy was performed immediately after an abnormal
VIA/VILI or, in case of a positive Pap smear or HCII, at the
second appointment. All women who attended consulta-
tions at the Campinas University Hospital (CAISM, 872
cases) and in Buenos Aires (2881 cases; see Figure 1) were
examined with screening colposcopy. In the other study
centres, 5% of the women with negative screening exams
were randomly assigned for colposcopic assessment. Ran-
dom assignment was performed in the interim between
collection and processing of the screening tests and the first
visit to be appraised of the test result, the women being
informed of her assignment status at that moment. All
examinations were performed by experienced and certified
colposcopists. Careful examination of the cervix and
transformation zone was carried out approximately 1min
after applying 5% acetic acid on the entire cervix, with up to
40 magnification (DF Vasconcellos Inc., Brazil). Aceto-
white epithelium, punctuation, mosaic, iodine negativity
and atypical vessels prompted colposcopically targeted
punch biopsies.21
Cervical biopsies
Tissue samples were fixed in formalin, embedded in
paraffin, and processed into 5-mm-thick haematoxylin–
eosin-stained sections for light microscopy, following the
routine procedures. All biopsies were examined as part of
the daily routine in the Pathology Departments of the four
clinics, and diagnosed using the commonly agreed CIN
nomenclature. For the study purposes, the pathologists were
also asked to notify the morphological changes suggestive
for the presence of HPV in cases with no CIN (i.e. HPV-non
CIN [¼flat condyloma]). The slides from two of these
centres (Campinas, Sa˜o Paulo) have been subjected to
re-examination by a panel of pathologists from European
Union countries (ME, KS). The consensus diagnosis of the
panel was considered to be the final diagnosis, also
comprising the specific diagnostic categories used in
classifying cervical pathology. CIN 2 or worse was regarded
as a ‘clinically significant lesion’, whereas all other
histological subtypes of cervical disease were categorized as
‘non-significant’.
Statistical analysis
Colposcopy and cervical biopsies (i.e. punch biopsies or
cervical cones) were considered to be the reference investi-
gations. Women with pathologically confirmed CIN 2 or
worse were regarded as positive, whereas women with
normal colposcopy, abnormal colposcopy with non-CIN,
CIN 1, or other non-cancer diagnosis, or those who were not
examined with colposcopy but had all screening tests
negative, were considered to be negative. Differences in
women’s age distribution according to the study centres
have been tested through the paired t-test. Sensitivity,
specificity, positive and negative predictive values (PPV and
NPV) were calculated for all screening tests, alone and in
combination, by using the cervical biopsy as the gold
standard, with different cut-off points (CIN 2 or CIN 3). In
order to avoid distorted performance results, calculations
have been carried out after excluding all women with
abnormal colposcopy but no histological assessment, and
women with an abnormal screening test, therefore necessi-
tating a colposcopic assessment according to the study
protocol, but that did not show up for colposcopy or that did
not comply with the exam. All calculations were performed
with the R environment for statistical computing20 within
95% confidence intervals (95% CI).
RESULTS
Women’s age did not differ significantly between study
centres (P¼0. 89). Mean age was 37.9 years, with 90%
central range of 26–56 years (data not shown). Overall test
positivity was 11.6% for VIA, 23.0% for VILI, 2.2% for Pap
smear (LSIL threshold), 1.1% for Pap smear (HSIL thresh-
old) and 17.1% for HCII. The highest proportions of positive
VIA (17.3%) and VILI (33.4%) were found among women
aged 21–30 years, whereas women agedX41 years were less
likely to have a cervical abnormality with VIA (7.8%) or
VILI (19.5%). The highest proportions of women with
abnormal Pap tests (LSIL) were encountered among those
21–30 years old (2.4%) and 31–40 years (2.9%), whereas for
HSIL, the majority of abnormal tests concentrated in the
group of women aged 31–40 years (1.7%). No woman p20
years old presented with an HSIL Pap test. In contrast, HCII
positivity rates decreased with increasing age, as 38.1% of
women aged p20 years had a positive HPV test and only
10.9 of those aged X41 years had a positive HCII (Table 1).
Table1 Results of the screening tests in different age groups
Positive/total (% positive)
Age (years) VIA VILI Pap smear (LSIL) Pap smear (HSIL) HPV*
p20 51/355 (14.4) 14/57 (24.6) 5/307 (1.6) 0/307 (0.0) 53/139 (38.1)
21–30 531/3076 (17.3) 155/464 (33.4) 63/2648 (2.4) 15/2648 (0.6) 264/1070 (24.7)
31–40 397/3290 (12.1) 192/794 (24.2) 81/2773 (2.9) 47/2773 (1.7) 205/1204 (17.0)
X41 398/5113 (7.8) 327/1679 (19.5) 76/4410 (1.7) 52/4410 (1.2) 195/1782 (10.9)
Total 1377/11834 (11.6) 688/2994 (23.0) 225/10138 (2.2) 114/10138 (1.1) 717/4195 (17.1)
Detected with Hybrid Capture 2s
VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; HPV,
human papillomavirus
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Overall, histological specimens obtained with punch
biopsies or cervical conization disclosed 136 CIN 1, 54 CIN
2, 80 CIN 3 and 28 cases of cancer, totalling 162 cases of
significant (CIN 2 or worse) lesions. Normal cervical tissue,
or lesions rendered as acute colpitis, condyloma or HPV-non
CIN, were sampled from another 1312 women. Table 2
displays screening test results as related to the final
diagnosis. VIA was positive in 61.8% of the women with
CIN 1, 57.0% of those with CIN 2, 35.0% of those with CIN
3 and in 21 of 28 (75%) women with cancer. Approximately
10% of women with no detectable disease had an abnormal
VIA. Regarding VILI, 83.3% of women diagnosed with CIN
1 and 62.5% of those with CIN 3 had an abnormal test. VILI
failed to detect one of three cases of cancer. The rate of
abnormalities in Pap smears (regarded as positive with an
LSIL threshold) increased in parallel with the increasing
grade of the histological lesions, ranging from 14.2% among
women with CIN 1 to 76.9% among those diagnosed with
cancer. The same occurred with an HSIL threshold, ranging
from 3.5% positivity rate in women with CIN 1 to 76.9% in
women with squamous cancer. HPV tests were positive in
15.5% of women with no detectable disease, but were
positive in 52.3% of women with CIN 1, reaching 100.0%
(three of three cases) in women diagnosed with cancer.
Interestingly, 96.6% of women with CIN 3 had a positive
HCII, whereas only 67.7% of those with CIN 2, also
considered high-grade disease, had a positive HPV test
(Table 2).
Using the CIN 2 cut-off point, VIA and VILI as stand-alone
tests performed very similarly in terms of sensitivity,
detecting roughly 50% of the lesions (Table 3). However,
VIA was more specific (89%) than VILI (77%). Importantly,
both tests showed very low PPV: 6.6% for VIA and, even
more impressive, close to 3% for VILI. The NPV of VIA
(99.2 %) matched that of VILI (99.3%). Pap smear, with
LSIL and HSIL cut-off points, matched the sensitivity, but
were more specific than VILI and VIA. Pap smear detected
57.9% (95% CI 49.9–66.6%) of CIN 2 or worse lesions with
an LSIL cut-off point, and 52.1% (95% CI 44.1–60.2%) of
those with an HSIL cut-off point. Contrasting to the visual
Table 2 Screening test results as related to the final diagnosis
Positive/total (% positive)
Final diagnosis VIA VILI Pap smear (LSIL) Pap smear (HSIL) HPV
Negative* 1213/11536 (10.5) 637/2919 (21.8) 123/9878 (1.2) 34/9878 (0.3) 631/4067 (15.5)
CIN 1 84/136 (61.8) 30/36 (83.3) 16/113 (14.2) 4/113 (3.5) 34/65 (52.3)
CIN 2w 31/54 (57.4) 4/12 (33.3) 22/47 (46.8) 16/47 (34.0) 21/31 (67.7)
CIN 3w 28/80 (35.0) 15/24 (62.5) 44/74 (59.5) 40/74 (54.1) 28/29 (96.6)
Invasivew 21/28 (75.0) 2/3 (66.6) 20/26 (76.9) 20/26 (76.9) 3/3 (100.0)
Total 1377/11834 (11.6) 688/2994 (23.0) 225/10138 (2.2) 114/10138 (1.1) 717/4195 (17.1)
*All tests negative; normal colposcopy; abnormal colposcopy with histological diagnosis of: cervicitis, acute colpitis, condyloma, HPV-non CIN
w‘Significant’ lesions
VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; HPV,
human papillomavirus
Table 3 VIA and VILI used alone or combined with Pap test and HCII in detecting significant cervical pathology
Performance Sensitivity (95% CI) Specificity (95% CI) PPV NPV
CIN 2 cut-off point
VIA 50.0 (42.2–57.7) 89.7 (89.1–90.3) 6.6 99.2
Pap (HSIL) 52.7 (44.0–60.2) 99.7 (99.5–99.7) 72.8 99.3
Pap (LSIL) 57.9 (49.9–66.0) 98.7 (98.5–98.9) 41.2 99.4
HCII 82.8 (73.6–92.1) 86.4 (85.3–87.5) 8.9 99.7
VIA or Pap* 82.4 (76.3–88.4) 87.2 (86.5–88.0) 9.2 99.7
VIA and Pap* 25.5 (18.6–32.4) 99.8 (99.7–99.9) 63.3 99.0
VIA or HCII 95.4 (91.4–99.4) 66.3 (64.7–68.0) 6.1 99.8
VIA and HCII 25.2 (17.3–33.2) 99.0 (98.8–99.2) 21.8 99.2
VILI 56.7 (40.8–72.7) 77.9 (76.2–79.7) 3.1 99.3
VILI or Pap 96.8 (93.4–100.0) 74.0 (72.1–75.7) 10.9 99.9
VILI and Pap* 14.9 (8.3–29.4) 99.8 (99.8–99.9) 48.3 99.3
VILI or HCII 100.0 (100.0–100.0) 39.3 (35.7–42.8) 5.7 100.0
VILI and HCII 51.3 (45.3–57.3) 80.9 (76.1–85.6) 31.7 90.5
CIN 3 cut-off point
VIA 45.4 (35.9–54.6) 89.5 (88.9–90.1) 4.0 99.4
Pap (HSIL) 59.0 (49.8–68.6) 99.5 (99.3–99.6) 57.3 99.6
Pap (LSIL) 64.0 (54.6–73.4) 98.4 (98.2–98.7) 31.4 99.6
HCII 97.0 (91.1–100.0) 86.0 (84.8–87.2) 5.3 100.0
VIA or Pap* 81.4 (73.8–89.0) 86.9 (86.1–87.5) 6.1 99.8
VIA and Pap* 28.3 (19.7–36.9) 99.7 (99.6–99.8) 50.0 99.3
VIA or HCII 98.5 (95.7–100.0) 65.8 (64.2–67.5) 4.0 99.9
VIA and HCII 18.5 (9.1–26.9) 98.8 (98.6–99.0) 9.8 99.5
VILI 65.3 (47.1–83.7) 77.9 (76.2–79.6) 2.5 99.6
VILI or Pap 97.3 (93.6–100.0) 74.3 (72.5–76.2) 8.4 99.9
VILI and Pap* 18.9 (8.3–29.4) 99.8 (99.7–99.9) 35.7 99.6
VILI or HCII 100.0 (100.0–100.0) 38.7 (35.2–42.3) 3.7 100.0
VILI and HCII 59.3 (53.3–65.2) 80.2 (75.4–85.0) 25.4 94.5
*With LSIL cut-off point
VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; HCII, Hybrid
Capture II; PPV, positive predictive value; NPV, negative predictive value
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tests, Pap smear reached 99.7% and 98.7% specificity rates
at HSIL and LSIL cut-off points, also outperforming VIA and
VILI in regards to PPV and NPV. HCII was the most sensitive
stand-alone test (82.8%; 95% CI 73.6–92.1%), but by far
the less specific (86.4%; 95% CI 85.3–87.5%).
Completely different performance figures are obtained
when VIA and VILI are combined with Pap smear and HCII.
When VIA and Pap were both positive, only 25.5% of
the women had CIN 2 or worse, but there is a significant
gain in specificity from 89.7% to 99.8%, as well as in PPV
(6.6–63.3%). The same was also true with VILI. Combining
with HCII increased the specificity and PPV of both VIA
and VILI and also the NPV of VILI, compromising their
sensitivity. Nevertheless, when the combination of exams
was considered as positive when at least one of them
was positive, the combination VILI or HCII was the most
sensitive (100%), but VIA and HCII combination and VIA or
Pap were also highly sensitive. Of course, specificity suffers
with this approach, dropping to 87.2% in the case of VIA or
Pap, 66.3% with VIA or HCII and 74.0% with VILI or Pap,
and only 39.3% with VILI or HCII. The same has occurred
with the PPV.
With the CIN 3 cut-off point, performance indicators of
VIA and VILI differed only slightly from those obtained with
CIN 2. HCII was still the most sensitive stand-alone test,
reaching 97.0% (95% CI 91.1–100.0%) sensitivity versus
45.4 (95% CI 35.9–54.6%) of VIA, but was slightly exceeded
by VIA in specificity: 89.5% (95% CI 88.9–90.1%). The
effects of combining with Pap test and HCII were similar as
those described with the CIN 2 cut-off point (Table 3).
DISCUSSION
Most of the previous reports addressing the test performance
indicators of VIA and VILI have been carried out in
developing countries. Investigators from India and some
sub-Saharan countries have significantly contributed to our
current knowledge regarding the potential of direct visual
assessment of the cervix, by examining large cohorts to
assess these tests in large-scale screening settings.3,8,12 These
previous studies have been conducted in a multitude of
health services and different economic backgrounds, ran-
ging from extremely poor and unassisted regions to areas
with moderately developed health care structures.8,9,12
Although Brazil and Argentina are still considered develop-
ing countries and still have relatively elevated overall
mortality rates due to cervical cancer, the national regions
where the LAMS study is being run14 certainly do not
equate with regard to cervical disease burden with those
countries where the most extensive testing of VIA and VILI
have been made.1,2,14,15 While comparing the results of the
present study with those previous reports, therefore, we
should take into account the differences in these screening
settings, which in our case represent a mixture of regions
with moderately- to well-developed preventive health care.
For instance, in the state of Sa˜o Paulo, including our centres
in Campinas and Sa˜o Paulo, cervical cancer accounted for
3.5% of all female cancer deaths in 1995–99.14 In Porto
Alegre, cervical cancer is only the sixth most common cause
of cancer deaths among women, totalling 6.1% of all female
deaths due to cancer. In Argentina, estimated cervical cancer
mortality was 7.6 per 100.000 women in the year 2000.15
The fact that a substantial proportion of the subjects have
been tested for HPV using HCII assay is noteworthy: this
testing provides information that most of the prior VIA/VILI
studies lack, but which must be considered critical for the
understanding of the disease dynamics in the studied
population.21–25
In this cohort of almost 11,500 women, abnormal patterns
in both VIA and VILI were more common among those who
presented with LSIL and HSIL in their cervical Pap smears
compared with those women with normal cytology (data
not shown). This significant association of abnormal VIA
and VILI with cytological abnormalities suggests that both
tests have a potential to detect cervical disease. Unfortu-
nately, however, the high numbers of women with an
abnormal pattern in VIA/VILI raised our concern about the
misleading false-positive images found by the naked-eye
examiners. In a series of 2754 African women, Denny et al.11
found that 29.4% of the women aged 35–39 years and
23.4% of those aged 50–65 years had a positive VIA, which
are significantly higher figures as compared with the 11.6%
overall positivity rate in the present study. A part of this
difference is probably explained by the different incidence of
cervical disease among the African and Brazilian popula-
tions, but, more importantly, may reflect the difficulties in
reproducing the same criteria of categorizing the findings in
the visual inspection. Sankaranarayanan et al.,7 who
examined 3000 Indian women, trained paramedical per-
sonnel to grade the aceto-white lesions as positive only
when a distinct pattern was noted, considering faint and
doubtful aceto-whitening as a negative VIA result. We tried
to adopt the same policy, but even then an unacceptable
proportion of women were classified as VIA-positive in
whom no cervical lesions were detected on colposcopy, Pap
smear or biopsy. With even graver consequences to the
performance of the exam, VILI was considered positive in
23.0% of all study subjects and 33.4% of those aged 21–30
years. This high number of false-positive results yielded a
specificity of less than 80% and PPV that, for high-grade
disease, did not surpass 2.5%. Even mild abnormalities of
the uterine cervix, highly prevalent in young women, may
possibly confound VILI examiners. In the present study,
nurses and doctors performed the visual tests after being
trained to render a diagnosis based upon the Atlas of Visual
Inspection.8 However, the exact numbers of VIA/VILI
performed by each of these professionals (doctors versus
nurses) have not been recorded, thus precluding the
investigators to assess whether nurses and doctors differed
in their performances as naked-eye examiners of VIA and
VILI.
In the present series, the proportion of women with
positive HPV tests was far higher than that of women with
abnormal Pap smears. Despite this fact, however, HCII
results did not concur with those of VIA/VILI any better
than did the Pap test. In their study on African women,
Denny et al.11 found a 20% HPV prevalence, ranging from
22.4% among women aged 35–39 years to 17.1% among
those aged 50–65 years, which are in perfect alignment with
the figures of the present study. Similarly, HCII prevalence
was also significantly higher among VILI-positive women in
our study, but there are no published data reporting the
associations of HPV and VILI. In the study by Denny and
colleagues, the sensitivity of VIA in detecting high-risk HPV
was 13%, specificity 88%, PPV 29% and NPV 84%, the
corresponding figures for VILI being 45%, 69%, 24% and
85%.
Owing to their subjective visual nature, VIA and VILI
should, at least in theory, correlate well with the colposcopic
findings. This could not be confirmed in the present study,
however. Colposcopy did not confirm almost 50% of the
abnormalities in VIA or almost 65% of those in VILI. More
importantly, close to 25% of the women considered as
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having a normal cervix on VIA actually had a significant
abnormality detected on colposcopy, as did 12% of the
women categorized as normal with VILI. Like all studies
where less than 100% of the women are examined by the
test used as the gold standard, the present study suffers from
verification bias. Only those women who are referred to
colposcopy on the basis of a positive screening test (Pap,
VIA, VILI, HCII) and almost 3500 women subjected to
screening colposcopy or randomly assigned to this exam had
the chance to become examined by the agreed gold standard
(i.e. cervical biopsy). Thus, some women with true cervical
abnormalities who tested negative with VIA, VILI, HCII
and Pap smear might still remain undisclosed, resulting in
over-optimistic performance indicators of the screening
tests used.
In a cohort of 4444 women examined with Pap smear,
VIA and VILI in Kerala, India, Sankaranarayanan et al.9
recently achieved more than 80% sensitivity and specificity
with VIA, associated with 17.5% PPV. In our hands, VIAwas
far less sensitive, but showed comparable specificity and
lower PPV. The results were equal with VILI, which reached
87.2% sensitivity, 84.7% specificity and 16.6% PPV,7 clearly
superior to our present results. While comparing these
different performance indicators, however, it is essential to
remember that these are dramatically influenced by the
prevalence of the cervical disease in the study populations,
and also on the use of the gold standard. One plausible
explanation for these discrepancies might be the shorter
experience of our investigators on the use of VIA and VILI,
contributing to the failure of reproducing the high-perfor-
mance indicators, especially sensitivity, of VIA and VILI in
the African and Indian series. It is sensible to presume,
however, that trained doctors experienced at performing
colposcopy should render visual assessments of the cervix
better than nurses or technicians. The PPV figures are
probably representative of the lower incidences of cervical
lesions in the present series compared with Indian and
African populations.
Combining VIA and VILI with Pap smear and HPV testing
markedly improved their performance as screening tools.
Many ongoing studies are paving the way for new screening
strategies for cervical cancer.4,8,9,12 These reports are almost
universally consonant in that the combination of screening
techniques may improve the overall sensitivity and, in some
instances, specificity and predictive values. However, stra-
tegies to deal with the increasing costs and the larger
number of women to be referred for colposcopy need to be
developed further.
For screening purposes, investigators should devise
strategies that provide reasonable detection rates and avoid
false positives. This obvious and simple assertion represents
the most important challenge in regard to cervical cancer,
because either detection rates or specificity of the screening
tests currently available for pre-invasive cervical neoplasia
demand improvements. In the present study, for instance,
Pap smear failed to detect almost 24% of the cancer cases. In
recent years, investigators have been able to clearly
demonstrate these inherent problems of screening, and the
results of the present report are in close alignment with
these previous findings. VIA, VILI, Pap smear and HCII
showed their flaws as stand-alone tests: combinations of
tests provided some improvement in terms of specific
performance indicators, but always at the expense of the
other indicators. Specifically addressing VIA and VILI,
despite the fact that we failed to reproduce the previously
reported performance figures with these unaided visual
methods as stand-alone tests in our screening settings, the
present data clearly demonstrate an improvement of both
VIA and VILI as screening tools when these visual methods
were used together with conventional Pap smears and HCII
assays for HPV detection. This is in alignment with the
current efforts made in several ongoing studies to develop
and test new innovative screening strategies, tailored
according to the local demands and by taking into account
the economical and social characteristics of each individual
setting. The results of the present investigation suggest that
VIA and VILI do not – in settings with prevalence of cervical
disease similar to that encountered were the LAMS study is
being run – deserve investment as major screening strate-
gies, or as adjunctive screening tools.
This is also one of the key aims of the ongoing
LAMS study, where eight different diagnostic tests are
compared as potential screening tools in Latin American
settings. It is to be anticipated that the optimal results
are most probably achievable by an innovative combi-
nation of two or more of these tests, but highly sensitive
and specific screening strategies have not yet been
devised.
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